OXB to demonstrate how its global, multi-vector CDMO platform is positioned to capture growth in the cell and gene therapy ...

Oxford, UK – 21 March 2025: OXB (LSE: OXB) (the "Company"), a quality and innovation-led cell and gene therapy CDMO, today announces that the Company has been recognised as a winner in the 'Cell & ...

OXB, a U.K.-based cell and gene therapy manufacturer, expanded its ongoing partnership with Bristol Myers Squibb to supply lentiviral vectors for the pharma giant’s CAR-T programs. The newly expanded ...

Live webcasts and recordings of presentations, where available, will be accessible under ‘Results, Reports, Presentations & Webcasts’ in the Investor Relations section of OXB’s website at www.oxb.com.

Oxford, UK – OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, has been honoured with a spot on the Financial Times’ prestigious ‘UK Best Employers 2025’ list. This ...

OXB to become commercial manufacturer of lentiviral vectors for Bristol Myers Squibb (BMS) CAR-T programmes Multi-year agreement with five-year initial term and option to extend Oxford, UK - 4 ...

Progression to full ownership aligns with global strategy and supports long-term growth in the viral vector manufacturing market Oxford, UK – 23 June 2025: OXB (LSE: OXB) (“the Company”), a global ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Oxford, UK - 21 March 2025: OXB (LSE: OXB) (the "Company"), a quality and innovation-led cell and gene therapy CDMO, today announces that the Company has been recognised as a winner in the 'Cell & ...